Building B
11 HaMenofim Street
Herzliya 4672562
Israel
972 9 799 6183
https://www.neurosense-tx.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 18
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Yael Barak | VP of Quality & Compliance | N/A | N/A | 1970 |
Ms. Keren Pushett | Head of HR | N/A | N/A | N/A |
Mr. Eidan Loushi | C.R.A. | N/A | N/A | N/A |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.